Literature DB >> 8953068

Prevalence of parvovirus B19 infection in patients infected with human immunodeficiency virus.

A M van Elsacker-Neile1, F P Kroon, M E van der Ende, M M Salimans, W J Spaan, A C Kroes.   

Abstract

Parvovirus B19 infection may cause chronic anemia in human immunodeficiency virus (HIV)-infected hosts. Small-scale studies and case reports have suggested that parvovirus B19 infection is a significant cause of anemia in HIV-infected patients. We studied single serum samples from 317 consecutive HIV-infected patients with use of parvovirus B19-specific serology and polymerase chain reaction for detection of viral DNA. Anemia was noted in 176 patients (55.5%); 126 (39.9%) had < 0.10 x 10(9) CD4+ cells/L. In this study group, 191 (60.3%) of the patients were positive for parvovirus B19 IgG. Seroprevalence rates did not differ between patients with low and higher CD4+ cell counts or between anemic and nonanemic patients. Parvovirus B19 DNA was detected in none of the sera. In a control group of 226 healthy male blood donors, the seroprevalence of parvovirus B19 IgG was 68.1%; two IgG-positive sera also contained parvovirus B19 DNA. This study demonstrates that chronic parvovirus B19 infection should not be considered a frequent cause of anemia in HIV-infected individuals.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8953068     DOI: 10.1093/clinids/23.6.1255

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

1.  Quantitative direct probe method for the detection of parvovirus B19.

Authors:  H Boggino; D A Payne
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

2.  A Persistent Parvovirus Infection Causing Anemia in an HIV Patient Requiring Intravenous Immunoglobulin Maintenance Therapy.

Authors:  Dhairya Gor; Vinit Singh; Varsha Gupta; Michael Levitt
Journal:  Cureus       Date:  2022-04-30

3.  Human immunodeficiency virus/human parvovirus B19 co-infection in blood donors and AIDS patients in Sichuan, China.

Authors:  Miao He; Jiang Zhu; Huimin Yin; Ling Ke; Lei Gao; Zhihong Pan; Xiuhua Yang; Wuping Li
Journal:  Blood Transfus       Date:  2012-06-27       Impact factor: 3.443

4.  Clinical features and laboratory findings of human parvovirus B19 in human immunodeficiency virus-infected patients.

Authors:  Renata Freire Alves Pereira; Rita de Cássia Nasser Cubel Garcia; Kátia Martins Lopes de Azevedo; Sérgio Setúbal; Marilda Agudo Mendonça Teixeira de Siqueira; Solange Artimos de Oliveira
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-04       Impact factor: 2.743

5.  The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa.

Authors:  Chabo Byaene Alain; Lufimbo Katawandja Antoine; Bizeti Nsangu Bizette; Pambu Dahlia; Tshibuela Beya Dophie; Muwonga Masidi Jérémie; Kayembe Nzongola-Nkasu Donatien; Ahuka Mundeke Steve
Journal:  Pan Afr Med J       Date:  2020-03-10

6.  Parvovirus B19 DNA detection in treatment-naïve HIV anemic patients in Lagos, Nigeria: a case control study.

Authors:  Oluwaseyi Sedowhe Ashaka; Olumuyiwa Babalola Salu; Ayorinde Babatunde James; Akeeb Oriowo Bola Oyefolu; AbdulAzeez Adeyemi Anjorin; Bamidele Oludare Oke; Mercy Remilekun Orenolu; Sunday Aremu Omilabu
Journal:  Afr Health Sci       Date:  2020-03       Impact factor: 0.927

7.  Status of immunity against PVB19 in HIV-infected patients according to CD4(+) cell count, and antiretroviral therapy regimen groups.

Authors:  Alireza Abdollahi; Saeed Shoar; Sara Sheikhbahaei; Behnaz Mahdaviani; Mehrnaz Rasoulinejad
Journal:  Niger Med J       Date:  2014-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.